Company Intelligence

PathAI

PathAI provides enterprise-grade artificial intelligence solutions, delivering specialized PathAI Platform technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.

Headquarters
Boston, United States
Founded
2016
Status
Active
Products
1
Reports
8
Last reviewed
Aug 2026

Overview

What this company is, what it builds, and who it serves.

PathAI is a Healthcare AI company based in Boston, United States, founded in 2016.

Boston digital pathology company applying AI to tissue analysis, with a announced Roche merger agreement pending close.

Verified founder profile on Brel: Andrew Beck.

What it does

Through the deployment of PathAI Platform, PathAI provides computational automation and data intelligence for organizations operating in Artificial Intelligence.

What it builds

PathAI Platform

Why It Matters

PathAI provides enterprise-grade artificial intelligence solutions, delivering specialized PathAI Platform technology designed to optimize mission-critical workflows across enterprise software developers and digital transformation teams.

Products

Products and platforms connected to this company.

Founders

People linked to this company in the Brel founder graph.

Ecosystem

How this company connects across the Brel AI intelligence graph.

Company

PathAI

Industry

Industries served

  • Digital Pathology

Capabilities

PathAI's core AI capability is computer vision applied to whole-slide images: convolutional and related deep-learning architectures trained to recognize patterns in stained…

Features

AI-powered digital pathology platform for analyzing histopathology slides, supporting diagnostic workflows, biomarker assessment, and pharmaceutical research use cases.

Country

United States

Use cases

Official Resources

Official and developer links on file for this company.

Latest Developments

Verified developments and timeline notes on file.

  • May 7, 2026: Roche announced a definitive merger agreement to acquire PathAI, with $750 million upfront consideration; the transaction had not closed as of this review. Latest
  • Company founded 2016 · founded Source
  • Development 2016 · development Source
  • Acquisition 2026 · acquisition Source

Acquisitions

  • May 7, 2026: Roche announced a definitive merger agreement to acquire PathAI, with $750 million upfront consideration; the transaction had not closed as of this review.

Frequently Asked Questions

What does PathAI do?

PathAI specializes in artificial intelligence, developing PathAI Platform to support enterprise software developers and digital transformation teams with scalable, production-grade technology.

Where is PathAI based and when was it founded?

PathAI is based in United States and was founded in 2016.

What are the main products offered by PathAI?

The flagship platform from PathAI is PathAI Platform, delivered primarily through b2b saas and enterprise api licensing.

Who are the primary target users of PathAI?

PathAI primarily serves enterprise software developers and digital transformation teams seeking reliable artificial intelligence implementations.

Sources & Verification

How this profile is verified and where the information comes from.

Verified
Last reviewed Aug 2026

Primary sources

Request a correction if you represent this company or believe information is inaccurate.